Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,550
Closed -$225K 314
2025
Q1
$225K Sell
3,550
-496
-12% -$36.5K 0.01% 276
2024
Q4
$306K Sell
4,046
-1,025
-20% -$80.5K 0.01% 236
2024
Q3
$448K Sell
5,071
-59
-1% -$4.63K 0.02% 195
2024
Q2
$387K Sell
5,130
-746
-13% -$69.3K 0.02% 203
2024
Q1
$552K Sell
5,876
-1,048
-15% -$107K 0.02% 187
2023
Q4
$752K Buy
6,924
+67
+1% +$7.2K 0.03% 164
2023
Q3
$656K Buy
6,857
+177
+3% +$18.2K 0.03% 162
2023
Q2
$737K Buy
6,680
+1,014
+18% +$119K 0.04% 154
2023
Q1
$695K Sell
5,666
-167
-3% -$20.5K 0.04% 153
2022
Q4
$683K Buy
5,833
+150
+3% +$15.1K 0.03% 153
2022
Q3
$472K Buy
5,683
+70
+1% +$7.54K 0.02% 172
2022
Q2
$573K Buy
5,613
+10
+0.2% +$1.18K 0.03% 158
2022
Q1
$755K Sell
5,603
-263
-4% -$37K 0.04% 148
2021
Q4
$979K Buy
5,866
+728
+14% +$120K 0.05% 138
2021
Q3
$746K Sell
5,138
-365
-7% -$59.5K 0.04% 136
2021
Q2
$853K Buy
5,503
+464
+9% +$62.4K 0.05% 123
2021
Q1
$674K Sell
5,039
-174
-3% -$24.2K 0.04% 129
2020
Q4
$737K Buy
5,213
+89
+2% +$11.8K 0.05% 126
2020
Q3
$646K Sell
5,124
-2
-0% -$215 0.05% 135
2020
Q2
$501K Sell
5,126
-1,312
-20% -$121K 0.05% 129
2020
Q1
$531K Sell
6,438
-770
-11% -$71.6K 0.05% 121
2019
Q4
$735K Sell
7,208
-127
-2% -$12K 0.07% 111
2019
Q3
$689K Sell
7,335
-1,157
-14% -$99.2K 0.06% 124
2019
Q2
$716K Sell
8,492
-946
-10% -$79.6K 0.06% 130
2019
Q1
$800K Sell
9,438
-1,358
-13% -$112K 0.07% 128
2018
Q4
$802K Sell
10,796
-290
-3% -$21.7K 0.06% 118
2018
Q3
$947K Sell
11,086
-459
-4% -$36.9K 0.08% 111
2018
Q2
$920K Sell
11,545
-978
-8% -$68.9K 0.08% 107
2018
Q1
$832K Buy
+12,523
New +$826K 0.07% 119
2017
Q4
Sell
-16,752
Closed -$869K 141
2017
Q3
$869K Sell
16,752
-1,673
-9% -$93.9K 0.07% 116
2017
Q2
$1.09M Sell
18,425
-2,497
-12% -$135K 0.09% 106
2017
Q1
$1.17M Buy
20,922
+295
+1% +$16.3K 0.1% 107
2016
Q4
$1.05M Buy
+20,627
New +$1.06M 0.09% 107

Other funds holding NKE

Aspiriant LLC's NKE Position: Q2 2025 in Review

Aspiriant LLC sold out of Nike (NKE) in Q2 2025, closing a stake of 3,550 shares — an estimated $225K sold.

Aspiriant LLC first reported a position in NKE in Q4 2016 and held it in 33 quarters. The position peaked at $1.17M in Q1 2017. 2,064 funds tracked by Wall St. Rank hold NKE as of Q2 2025.

  • Aspiriant LLC reported no remaining Nike position as of Q2 2025 after selling out during the quarter.
  • Aspiriant LLC sold 3,550 Nike shares in Q2 2025, an estimated $225K.
  • Aspiriant LLC first reported a position in Nike in Q4 2016 and held it in 33 quarters.
  • Aspiriant LLC's Nike position peaked at $1.17M in Q1 2017.
  • 2,064 funds tracked by Wall St. Rank held Nike as of Q2 2025.

Based on Aspiriant LLC's 13F filing for Q2 2025, filed 29 Jul 2025.